RNAZ (TransCode Therapeutics, Inc. Common Stock) Stock Analysis - Politician Trades
TransCode Therapeutics, Inc. Common Stock (RNAZ) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAZ trades at $6.35 with a market cap of $5.66M and a P/E ratio of -0.12. RNAZ moved +0.00% today. Year to date, RNAZ is -17.43%; over the trailing twelve months it is -25.12%. Its 52-week range spans $5.56 to $739.20. Rallies surfaces RNAZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded RNAZ stock?
Rallies tracks politician and congressional stock disclosures for RNAZ, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Fitzgerald Thomas A bought 49.35K (~$25.17K) on Sep 28, 2023.
Dudley Robert Michael bought 98.00K (~$49.98K) on Sep 28, 2023.
Dudley Robert Michael bought 12.00K (~$31.82K) on Jun 21, 2023.
RNAZ Analyst Consensus
RNAZ analyst coverage data. Average price target: $0.00.
Common questions about RNAZ
Which politicians traded RNAZ stock?
Rallies tracks politician and congressional stock disclosures for RNAZ, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in RNAZ?
Yes. Rallies tracks politician and congressional stock disclosures for RNAZ, including reported purchases, sales, dates, owners, and trade amounts when available.
Is RNAZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RNAZ. It does not provide personalized investment advice.
